San Diego, CaliforniaMay 20, 2026 /PRNewswire/ — On May 19, 2026, Illumina, Inc. (NASDAQ: ILMN) released its annual Corporate Responsibility Report. The report highlights the company’s ongoing progress in advancing equitable access to genomics, delivering measurable impact for patients, communities, and healthcare systems worldwide, further underscoring Illumina’s mission-driven culture, sustainability goals, and long-term commitment to driving “genomics for good.”
“Every year, over 20 million people are diagnosed with cancer, rare disease patients often wait years for a diagnosis, and healthcare systems face pressure to improve health outcomes with increasingly constrained resources. Genomics can help address these challenges, but only if it is broadly integrated into real-world settings,” said Jacob Thaysen, CEO of Illumina. “In 2025, the sequencing volume completed on Illumina platforms was equivalent to more than 10 human genomes per minute. This significant progress shows we are seizing a pivotal moment to accelerate toward a future where personalized medicine benefits more people and delivers better health outcomes.”
Driving Scalable Access to Genomics Worldwide
Illumina continues to advance cost-effective and scalable technologies while advocating for and driving global policies and initiatives to improve access to genomic medicine. In 2025, the company partnered with governments, healthcare systems, and research institutions to advance large-scale population genomics, sovereign data governance, and national precision health programs tailored to local needs. The Illumina Corporate Foundation supported global initiatives to extend next-generation sequencing to previously underserved patient populations. The company also engaged in international policy efforts to prioritize rare diseases in public health agendas and actively participated in rare disease-themed hackathons, leveraging new technologies and employee expertise to collaboratively address challenges in genomics.
Continued Leadership in Sustainability and Community Engagement
Recognizing that human health and environmental health are inextricably linked, Illumina continues to reduce its environmental impact across all business operations and support customers in conducting sequencing more sustainably. Since 2019, the company has reduced product packaging by 87%, surpassing its 2030 target. Additionally, Scope 1 and Scope 2 greenhouse gas emissions have been reduced by 74%, and through the procurement of renewable energy, on-site solar installations, and the purchase of renewable energy certificates (RECs), Illumina has achieved 100% renewable electricity for the fourth consecutive year. For these efforts, Illumina has been named to *Time* magazine’s list of the “World’s Most Sustainable Companies” for two consecutive years.
Illumina is committed to supporting its employees and communities, achieving “zero net pay gap” for the seventh consecutive year and reaching its 2030 goal of 100,000 volunteer hours ahead of schedule. Since 2019, employees have contributed over 116,000 volunteer hours, with approximately 50% of employees participating in donation and volunteer activities in 2025. Illumina employees actively engage in educational outreach, bringing their professional passion into classrooms to nurture the next generation of scientists. Since 2019, the company has reached 2.6 million STEM learners, including 500,000 in 2025.
Through long-term innovation, Illumina continues to advance the broad application of genomic technology in research, clinical settings, and population health. In 2025, the company launched the Illumina 5-Base Solution and the Illumina Protein Prep proteomics solution, upgraded the DRAGEN software pipeline, and expanded its oncology portfolio. Additionally, Illumina introduced new capabilities such as PromoterAI and deepened collaborations with global partners, including the Genomics Discovery Alliance and the Broad Clinical Labs.
Illumina’s 2025 Corporate Responsibility Report comprehensively presents the above content. For more details, please refer to the full report.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including but not limited to those regarding Illumina’s expectations, plans, and the potential impact of its technologies and related initiatives, are based on the company’s current expectations, assumptions, and judgments. These forward-looking statements are subject to various risks and uncertainties, and actual results may differ materially from those expressed or implied in such statements. Forward-looking statements can often be identified by words such as “anticipate,” “believe,” “may,” “estimate,” “expect,” “plan,” “intend,” “possibility,” “potential,” “predict,” “seek,” “will,” and similar expressions. Factors that could cause actual results to differ materially include, but are not limited to: challenges inherent in the development and commercialization of new technologies; the rate of adoption of genomic solutions by customers and healthcare systems; regulatory developments and reimbursement policies; and other factors disclosed in Illumina’s filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Except as required by law, Illumina undertakes no obligation to update any forward-looking statements.
About Illumina
Illumina is dedicated to improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array technologies, serving customers in the research, clinical, and applied markets. Our products are used in life sciences, oncology, reproductive health, agriculture, and other emerging fields. For more information, please visit www.illumina.com or follow Illumina on WeChat.